India’s Shantha Said To Be Acquisition Target Of GSK, Sanofi
This article was originally published in PharmAsia News
Executive Summary
Two multinational drug makers are reported to be eyeing India's Shantha Biotech as an acquisition. Sources identified the two suitors as U.K.-based GlaxoSmithKline and French drug maker Sanofi-Aventis. Both firms are said to be holding separate talks with the French majority owner, Merieux Alliance, with GSK considered the front-runner. One source said Merieux seeks to sell its entire 80 percent stake in Shantha, valued at more than $196 million. GSK and Sanofi-Aventis said the reports were speculative and Merieux would not comment. (Click here for more